Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C11H11NO4S |
| Molecular Weight | 253.274 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@]1(CSC(=N1)C2=CC=C(O)C=C2O)C(O)=O
InChI
InChIKey=OEUUFNIKLCFNLN-LLVKDONJSA-N
InChI=1S/C11H11NO4S/c1-11(10(15)16)5-17-9(12-11)7-3-2-6(13)4-8(7)14/h2-4,13-14H,5H2,1H3,(H,15,16)/t11-/m1/s1
| Molecular Formula | C11H11NO4S |
| Molecular Weight | 253.274 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Deferitrin is a desferrithiocin-derived hexadentate iron chelator, developed by Genzyme Corp. for the treatment of severe iron overload in people who require repeated erythrocyte transfusion for the management of chronic anemia such as beta-thalassemia major. Development of the drug was halted after phase 1/2 clinical trial due to nephrotoxicity.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 05:42:40 GMT 2023
by
admin
on
Sat Dec 16 05:42:40 GMT 2023
|
| Record UNII |
T69Y9LDN44
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
178603
Created by
admin on Sat Dec 16 05:42:40 GMT 2023 , Edited by admin on Sat Dec 16 05:42:40 GMT 2023
|
||
|
NCI_THESAURUS |
C62357
Created by
admin on Sat Dec 16 05:42:40 GMT 2023 , Edited by admin on Sat Dec 16 05:42:40 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
T69Y9LDN44
Created by
admin on Sat Dec 16 05:42:40 GMT 2023 , Edited by admin on Sat Dec 16 05:42:40 GMT 2023
|
PRIMARY | |||
|
8569
Created by
admin on Sat Dec 16 05:42:40 GMT 2023 , Edited by admin on Sat Dec 16 05:42:40 GMT 2023
|
PRIMARY | |||
|
C120073
Created by
admin on Sat Dec 16 05:42:40 GMT 2023 , Edited by admin on Sat Dec 16 05:42:40 GMT 2023
|
PRIMARY | |||
|
QQ-46
Created by
admin on Sat Dec 16 05:42:40 GMT 2023 , Edited by admin on Sat Dec 16 05:42:40 GMT 2023
|
PRIMARY | |||
|
SUB26251
Created by
admin on Sat Dec 16 05:42:40 GMT 2023 , Edited by admin on Sat Dec 16 05:42:40 GMT 2023
|
PRIMARY | |||
|
239101-33-8
Created by
admin on Sat Dec 16 05:42:40 GMT 2023 , Edited by admin on Sat Dec 16 05:42:40 GMT 2023
|
PRIMARY | |||
|
CHEMBL432481
Created by
admin on Sat Dec 16 05:42:40 GMT 2023 , Edited by admin on Sat Dec 16 05:42:40 GMT 2023
|
PRIMARY | |||
|
C76597
Created by
admin on Sat Dec 16 05:42:40 GMT 2023 , Edited by admin on Sat Dec 16 05:42:40 GMT 2023
|
PRIMARY | |||
|
135413558
Created by
admin on Sat Dec 16 05:42:40 GMT 2023 , Edited by admin on Sat Dec 16 05:42:40 GMT 2023
|
PRIMARY | |||
|
EU/3/03/180(WITHDRAWN)
Created by
admin on Sat Dec 16 05:42:40 GMT 2023 , Edited by admin on Sat Dec 16 05:42:40 GMT 2023
|
PRIMARY | Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in June 2009 on request of the sponsor. On 12 December 2003, orphan designation (EU/3/03/180) was granted by the European Commission to Genzyme Europe BV, the Netherlands, for 4,5-dihydro-2-(2,4-dihydroxyphenyl)-4-methylthiazole-4(S)-carboxylic acid (GT56-252) for the treatment of chronic iron overload requiring chelation therapy. | ||
|
100000091270
Created by
admin on Sat Dec 16 05:42:40 GMT 2023 , Edited by admin on Sat Dec 16 05:42:40 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
